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carcinoembryonic antigen: a feasibility study for
clinical use
Che-Chuan Yang1, Shieh-Yueh Yang1*, Chia-Shin Ho1, Jui-Feng Chang1, Bing-Hsien Liu1 and Kai-Wen Huang2,3Abstract
Background: Magnetic nanoparticles functionalized antibodies are used for in-vitro assays on bio-markers. This work
demonstrates the synthesis of high-quality magnetic nanoparticles coated with antibodies against carcinoembryonic
antigen (CEA). Various characterizations, such as particle size, particle suspension, bio-activity and the stability of
bio-magnetic nanoparticles suspended in liquid, are studied. The properties for the assay of CEA molecules in serum
are also studied. The assay method used is so-called immunomagnetic reduction.
Results: The results show that the effects of common materials in serum that interfere with detected signals are
not significant. The low-detection limit is 0.21 ng/ml, which is well below the clinical threshold of 2.5 ng/ml.
Conclusions: The dynamic range for the assay of CEA molecules in serum is 500 ng/ml. By assaying serum CEA
molecules from 24 normal controls and 30 colorectal-cancer patients, the threshold for the serum-CEA concentration to
diagnose colorectal cancer is 4.05 ng/ml, which results in a clinical sensitivity of 0.90 and specificity of 0.87.
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Bio-functionalized magnetic particles are used in biomedi-
cines. Different bio-applications require different sizes of
magnetic particles. For example, because each particle is
strongly magnetized, magnetic particles with micrometer
diameters are useful for in-vitro extraction or purification
of bio-molecules such as antibodies, proteins and nucleic
acids [1-3]. Magnetic nanoparticles with sub-micrometer
diameters are used to sort specific cells in vitro, [4-6]. The
main reason for the use of sub-micro-particles instead of
micro-particles for cell sorting is to suppress the immuno-
logical responses from cells that are bound with magnetic
particles. Nano-scaled magnetic particles are mostly used
for in-vivo targeting or delivery, e.g. as a contrast medium
for magnetic resonance imaging, vectors for drug deliv-
ery and for hyperthermia [7-10]. In the late 1990’s, the
in-vitro quantitative detection of bio-molecules using* Correspondence: syyang@magqu.com
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unless otherwise stated.antibody functionalized magnetic nanoparticles was pro-
posed [11-13]. This is referred to as a magnetically labeled
immunoassay (MLI).
There are several types of MLI: sandwiched MLI
[12,14,15], wash-free MLI [11,13] and single-probe MLI
[11,13,16]. Different types of magnetic signals are detected
for various types of MLI, including, ac magnetic suscepti-
bility [15], magnetic relaxation [11], magnetic remanence
[12], phase lag for ac magnetization [17], nuclear magnetic
resonance [18] and magnetic reduction [13] and these are
related to the concentrations of bio-molecules that are to
be detected. In addition to this academic innovation, the
literature shows that MLI is a promising method for
in-vitro diagnosis in clinics. Since the early part of this
century, some MLI technology has been commercialized
in the US [19], France [20], Germany, Sweden [21], Japan,
China [22] and Taiwan [23]. There has been continuing
investment in the development, the commercialization
and the marketing of MLI, worldwide.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
















Figure 1 Anti-CEA functionalized magnetic nanoparticle. The
schematic composition and the distribution of the diameter of
anti-CEA functionalized magnetic nanoparticles are shown in (a) and
(b), respectively.
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used as labeling markers to target molecules. If a test sam-
ple has more target molecules, more magnetic nanoparti-
cles associate with target molecules. Ideally, each magnetic
nanoparticle is identical. Every nanoparticle has the same
size and magnetization. Each associated magnetic nano-
particle contributes equally to the magnetic signals. If
more magnetic nanoparticles associate with target mole-
cules, the magnetic signal is greater. The magnetic signals
are exactly correlated to the number of target molecules.
The precession of assay target molecules is high. However,
if the magnetic nanoparticles obviously differ from each
other and there is a broad variation in particle size, mag-
netic nanoparticles of different sizes contribute differently
to the magnetic signals. This results in a significant vari-
ation in the magnetic signals for a fixed number of associ-
ated magnetic nanoparticles, so the precision the assay of
target molecules is poor. For a MLI, it is important that
the bio-functionalized magnetic nanoparticles are uniform.
For a MLI, magnetic nanoparticles are suspended in solu-
tion as a reagent. When these nanoparticles agglomerate,
the binding area between the nanoparticles and the target
molecules is significantly reduced, which results in a re-
duced sensitivity and stability for detection, so the agglom-
eration of nanoparticles in a reagent must be inhibited.
Other required properties for the use of suspended bio-
functionalized magnetic nanoparticles as a reagent for in-
vitro diagnosis in clinics are the life time, the interference,
the low-detection limit, the sensitivity and the specificity.
Most previous studies have focused on the development
of either magnetic nanoparticles or detection methodolo-
gies, so there has been no complete study of the feasibility
of the clinical use of bio-functionalized magnetic nanopar-
ticles for in-vitro diagnosis. This study characterizes both
the particle properties and the assay features of antibody
functionalized magnetic nanoparticles. The target mol-
ecule is the carcinoembryonic antigen (CEA), which is the
clinical bio-marker for the in-vitro diagnosis of colorectal
cancer. The antibodies against CEA (anti-CEA) are immo-
bilized on magnetic nanoparticles. Various characteristics,
such as particle size, particle suspension, bio-activity and
the stability of the anti-CEA functionalized magnetic
nanoparticles suspended in liquid are studied. The assay
method used is the so-called immunomagnetic reduction.
Assaying CEA in serum allows features such as the inter-
ference, the low-detection limit, the dynamic range, the
clinic sensitivity and the specificity to be determined.
Results and discussion
Stability of magnetic nanoparticle suspension
The schematic composition of anti-CEA functionalized
magnetic nanoparticles is shown in Figure 1(a). The distri-
bution of anti-CEA functionalized magnetic nanoparticles
suspended in PBS solution in hydrodynamic diameter isshown in Figure 1(b). The mean value and the standard
deviation of the hydrodynamic diameter are found to be
51.3 nm and 13.51 nm, respectively, as measured using dy-
namic laser scattering. Hereafter, the anti-CEA functional-
ized magnetic nanoparticles suspended in PBS solution
are referred to as CEA reagent. The CEA reagent was
stored at 2–8°C. During the storage, the mean value and
standard deviation for the hydrodynamic diameter of anti-
CEA functionalized magnetic nanoparticles were moni-
tored. The results are shown in Figure 2, as dots with error
bars. The error bars correspond to the standard deviation
of the hydrodynamic diameter of anti-CEA functionalized
magnetic nanoparticles. It is obvious that the particle
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Stored at 2-8 oC
Figure 2 Stability tests, in terms of the mean diameter (•) and the
bio-activity (✝) of anti-CEA functionalized magnetic nanoparticles
dispersed in PBS solution, stored at 2–8°C.
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Figure 3 Stability tests for the bio-activity of anti-CEA functionalized
magnetic nanoparticles dispersed in PBS solution, stored at 25°C
using immunomagnetic reduction. The p values for the IMR signals
with respect to the initial IMR signals are plotted.
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2–8°C for 12 months. This shows that there is no signifi-
cant agglomeration of the anti-CEA functionalized mag-
netic nanoparticles in CEA reagent that is stored at 2–8°C
for 12 months. Namely, the suspension of anti-CEA func-
tionalized magnetic nanoparticles remains stable for
12 months. The stability of the suspension of the nanopar-
ticles in the reagent is important for clinic use. When
nanoparticles agglomerate, the association area between
antibodies and target molecules varies. The output signal
decays as the association area is reduced. The assay result
is unreliable, if there is any agglomeration of nanoparticles.
Fortunately, the results shown as dots in Figure 2 demon-
strate the high stability of the suspension of anti-CEA
functionalized magnetic nanoparticles in PBS solution,
stored at 2–8°C.
The factors that mainly affect the stability of a nano-
particle suspension in solution are the nano-size and the
uniformity of the nanoparticles. If the nano-size is suffi-
cient, the buoyancy of the nanoparticle is strong enough
to cancel the gravitational force, so the nanoparticle is
suspended in solution. However, for a certain magnetic
nanoparticle in the reagent, there can be attractive or
repulsive magnetic interactions between the magnetic
nanoparticle and neighboring magnetic nanoparticles. If
the magnetic nanoparticles are highly uniform, these
magnetic interactions are isotropic. The resultant mag-
netic force that acts on this magnetic nanoparticle is
zero and the magnetic interactions with these magnetic
nanoparticles can be ignored. This nanoparticle is not
attracted by other particles because there are no aniso-
tropic magnetic forces. Magnetic nanoparticles do not
agglomerate because of the isotropic magnetic inter-
action between particles, so highly uniform magnetic
nanoparticles exhibit high stability in suspension in solu-
tion. The results shown in Figure 1(b) show the nano-
size and the high degree of uniformity of the anti-CEA
functionalized magnetic nanoparticles synthesized in thiswork. As a result, the CEA reagent is highly stable in a
suspension in PBS solution.
Stability of magnetic nanoparticle bio-activity
In addition to the suspension stability, the other important
measurement for the CEA reagent is the bio-activity dur-
ing storage at 2–8°C. To measure this, the IMR signals for
5-ng/ml CEA solution were detected using the CEA re-
agent, during the storage period. The measurements for
the storage period for the IMR signals for the 5-ng/ml
CEA solution are plotted in Figure 2, using crosses. The
IMR signals range from 1.67% to 1.76%, during storage at
2–8°C for nine months. There is no significant change in
the IMR signal for the 5-ng/ml CEA solution during nine
months of storage at 2–8°C. Therefore, the bio-activity of
the CEA reagent is stable for at least nine months, if the
CEA reagent is stored at 2–8°C.
Room-temperature stability of reagent
For the experimental results shown in Figure 2, the CEA
reagent was originally at 2–8°C and was then stored at a
room temperature of 25°C. The temperature of the CEA
reagent was gradually increased from 2–8°C to 25°C over
5 minutes. 40-μl CEA reagent was used for each IMR
measurement. The remainder of the CEA reagent was re-
place in storage at 2–8°C. When all of the samples were
ready, the stored CEA reagent was warmed to 25°C, from
2–8°C, for IMR measurements. This thermal circle could
easily damage the bio-activity of CEA reagent, so the CEA
reagent was maintained at 25°C, to allow continuous IMR
measurements for several samples. In order to determine
the bio-activity of CEA reagent stored at 25°C, the CEA
reagent was moved from a storage temperature of 2–8°C
to 25°C. After 5 minutes, the temperature of the CEA re-
agent reached 25°C and the CEA reagent was maintained
at 25°C for 24 hours. The time period in the x axis in
Figure 3 begins at the 5th minute after the reagent was
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signals for 5-ng/ml CEA solutions for the 25-°C CEA re-
agent were detected for 24 hours. The results are plotted
as dots in Figure 3. The IMR signals at the beginning, i.e.
time period =0, are used as a reference. The p values of
the IMR signals at other time points with respect to the
referenced IMR signal are plotted as crosses in Figure 3.
All of the p values are greater than 0.05, which means that
there is no significant difference in the IMR signals shown
in Figure 3. The results in Figure 3 show that the bio-
activity is stable for 24 hours, even if the CEA reagent is
stored at 25°C.
Interference tests
In clinics, serum is the sample that is used to assay CEA.
There are many other materials in serum, besides CEA.
These materials are referred as to interfering materials.
Interfering materials can cause false IMR signals, because
of the colors of bio-molecules or the non-specific associa-
tions between the interfering materials and antibodies on
the magnetic nanoparticles. The accuracy of an assay is
adversely affected if false IMR signals occur frequently, so
the contributions of the interfering materials to IMR sig-
nals for the assay of CEA in serum must be determined.
Serum can contain interfering materials such as hemo-
globin, bilirubin, or triglyceride because of common dis-
eases, such as hemolysis, jaundice or hypertriglyceridemia.
Other bio-materials that exist naturally in serum, such as
uric acid, rheumatoid factor, intra lipid or albumin, are
also interfering materials. Other interfering materials in-
clude drugs or chemicals in medicine that is used to treat
inflammatory diseases, viral and bacteria infections, can-
cers and cardiovascular disease. All of the natural bio-
materials and drugs or chemicals tabulated in Table 1 were
spiked into serum that had 5 ng/ml CEA. A 5-ng/ml CEA
solution was used because this CEA concentration is ap-
proximately the clinical threshold of CEA concentration
for the diagnosis of colorectal cancer (~2.5 to 5 ng/ml).
The concentrations of these interfering materials are also
listed in Table 1. It is worthy of note that the concentra-
tions of the interfering materials are much greater than or-
dinary levels. For example, the level of hemoglobin in the
blood of a patient with hemolysis is around 500 μg/ml.
The concentration of hemoglobin used in Sample No. 2 is
1000 μg/ml. The IMR signals for these 5-ng/ml CEA
serum solutions are listed in Table 1. The IMR signal for
the serum (Sample No. 1) with only 5-ng/ml CEA is used
as a reference. All of the other IMR signals for the serum
samples (Sample Nos. 2–32) with both 5-ng/ml CEA and
the interfering materials are compared with the reference
IMR signal. The corresponding p values calculated T-Test
and are shown in Table 1. The p values IMR signals for
the serum samples with interfering materials are greater
than 0.05, as shown in Table 1. This demonstrates that,with the exception of acetyl cysteine and furosemide, the
bio-molecules, drugs and chemicals listed in Table 1 do
not interfere with the assay for CEA in serum.
The false IMR signal that is caused by interfering ma-
terials is mainly attributable to two factors: the color of
the interfering materials and the non-specific associa-
tions between the interfering materials and antibodies
on the magnetic nanoparticles. The detection signal used
for IMR measurement is magnetic ac susceptibility,
which is not affected by the colors of the samples, the
reagents, or the interfering materials, so the color of the
interfering materials does not cause false IMR signals to
be generated.
The non-specific associations between the interfering
materials and antibodies on the magnetic nanoparticles
are inhibited if highly specific antibodies are used. An add-
itional suppression mechanism is activated during IMR
measurement. During the IMR measurement, the mag-
netic nanoparticles oscillate with the external ac magnetic
fields. Both the target and other bio-molecules that are
bound with antibodies on the oscillating magnetic nano-
particles experience centrifugal forces. At high oscillation
frequencies, the centrifugal force is increased. If the centri-
fugal force is stronger than the binding force between the
antibodies and non-target bio-molecules, the non-specific
binding is broken, so the centrifugal force must be weaker
than the specific binding force between the antibodies and
the bio-molecules that are to be detected. As a result, the
cross reactions are inhibited during IMR measurement. In
principle, this suppression mechanism for non-specific
binding between antibodies and non-target bio-molecules
is independent of the concentration of the target mole-
cules, such as CEA. A detailed discussion of this suppres-
sion mechanism is given in Ref. [24].
CEA-concentration dependent IMR signals
In addition to the detection of IMR signal for the 5-ng/ml
CEA serum sample, the IMR signals for serum samples
with CEA at various concentrations, from 0.1 ng/ml to
1000 ng/ml, were measured. The experimental results for
the relationship between the CEA-concentration and the
IMR signal (IMR(%)-ϕCEA) are plotted as dots in Figure 4(a).
The detailed results are tabulated in Table 2. The error bar
for each data point in Figure 4(a) corresponds to the
standard deviation for multiple detections of IMR signals
for a given test sample. The IMR signal gradually in-
creases, as the CEA concentration increases from 0.1 ng/
ml, and then almost becomes saturated at a CEA concen-
tration of 500 ng/ml. The IMR(%)-ϕCEA relationship is de-
scribed by the logistic function:
IMR %ð Þ ¼ A−B
1þ φCEAφo
 γ þ B ð1Þ
Table 1 Materials and concentrations used for interference tests for a CEA assay, using the IMR method
Sample no. Interfering material Concentration Mean IMR value (%) Standard deviation of IMR (%) p value
1 None - 1.70 0.021 -
2 Hemoglobin 10000 μg/ml 1.71 0.014 0.246
3 Bilirubin 600 μg/ml 1.66 0.021 0.100
4 Triglyceride 30000 μg/ml 1.72 0.007 0.167
5 Uric acid 200 μg/ml 1.69 0.021 0.150
6 Rheumatoid factor 500 IU/ml 1.68 0.014 0.246
7 Intra lipid 30000 μg/ml 1.67 0.007 0.099
8 Albumin 60000 μg/ml 1.67 0.014 0.150
9 Acetaminophen 300 μg/ml 1.72 0.007 0.167
10 Acetyl cysteine 150 μg/ml 1.68 0.021 0.223
11 Acetylsalicylic acid 500 μg/ml 1.74 0.021 0.100
12 Ascorbic acid 300 μg/ml 1.71 0.014 0.246
13 Atrovastatin 3 μg/ml 1.71 0.014 0.246
14 Furosemide 4000 μg/ml 1.70 0.014 0.404
15 Ibuprofen 1000 μg/ml 1.72 0.049 0.326
16 Levodopa 20 μg/ml 1.71 0.014 0.246
17 Methyldopa 200 μg/ml 1.72 0.014 0.150
18 Naprosyn sodium 500 μg/ml 1.66 0.021 0.100
19 Phenylbutazone 400 μg/ml 1.65 0.007 0.052
20 Prednisone 5 μg/ml 1.69 0.014 0.404
21 Tegafur with uracil 50 μg/ml 1.70 0.021 0.500
22 Theophylline 50 μg/ml 1.69 0.014 0.404
23 Warfarin 50 μg/ml 1.66 0.014 0.096
24 Ampicillin sodium 1000 μg/ml 1.67 0.021 0.146
25 Cefoxitin 2500 μg/ml 1.73 0.014 0.096
26 Cyclosporeine A 10 μg/ml 1.71 0.007 0.296
27 Doxycycline hyclate 50 μg/ml 1.68 0.021 0.223
28 Irinotecan 100 μg/ml 1.69 0.014 0.404
29 Lovastatin 2.5 μg/ml 1.72 0.014 0.150
30 Metronidazole 200 μg/ml 1.70 0.021 0.500
31 Oxaliplatin 100 μg/ml 1.72 0.014 0.150
32 Rifampicin 60 μg/ml 1.74 0.007 0.051
The concentration of the CEA in each sample is 5 ng/ml. The matrix is serum. The detected mean value and the standard deviation of each sample are listed. The
p values of IMR signals for other samples are calculated using the IMR signals for the pure CEA-serum sample as a reference and the results are listed in the
right-most column.
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data in Figure 4(a) to Eq. (1) gives values for these pa-
rameters of as A =1.05, B =3.22, ϕo =14.05, and γ =0.94.
The fitting curve is plotted as a solid line in Figure 4(a).
The coefficient of determination, R2, is 0.999.
The stability of the resulting logistic function Eq. (1)
depends on the stability of the reagent. Several factors,
such as the biodegradability of the antibodies on the
magnetic nanoparticles, the agglomeration of the mag-
netic nanoparticles and the de-magnetization of the
magnetic nanoparticles significantly affect the lifetime ofthe reagent. If these factors do not change, the charac-
teristics of the logistic function Eq. (1) are retained.
In Figure 2, the high stability of the particles’ suspension
and isolation in the reagent is demonstrated. The particle
size is plotted as a function of the storage time at 2–8°C.
The IMR signal for 5-ng/ml CEA solution is dependent
on storage time, which demonstrates the bio-active stabil-
ity of the antibodies on the magnetic nanoparticles. The
magnetization of the magnetic nanoparticles does not
change if the storage temperature remains lower than the
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Figure 4 Spiked-CEA-concentration-in-serum, ϕCEA, and (a) IMR signal and (b) the CEA concentration, ϕCEA-IMR, derived using the
immunomagnetic reduction method.
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lifetime of the reagent are unchanged, if the reagent is
stored at 2–8°C for 12 months, so it is expected that the
resultant logistic function Eq. (2) is stable over 12 months.
Low-detection limit of assaying serum CEA
In Eq. (1), A denotes the IMR signal as the CEA concentra-
tion approaches zero, so parameter A in Eq. (1) represents
the background level for the detection of IMR signals. This
non-zero background level is mainly due to the electronic
noise of the IMR analyzer and the dynamic equilibrium forthe association between the CEA molecules and anti-CEA
on the magnetic nanoparticles. Using the 3-σ criterion, the
low-detection limit for the assay of CEA in terms of the
IMR signal is (1.05 + 3 × 0.014)% =1.09%, where 0.014% is
the standard deviation of the IMR signals at low CEA con-
centrations, such as 0.1 ng/ml. Using Eq. (1), the CEA con-
centration that corresponds to the IMR signal of 1.09% is
0.21 ng/ml. Therefore, the low-detection limit for the assay
of CEA in serum using IMR is 0.21 ng/ml. It is significant
that the threshold of CEA concentration in serum for the
diagnosis of colorectal cancer is 2.5 ng/ml. The IMR
Table 2 CEA concentrations, ϕCEA, spiked in serum, for
the detections of IMR signals







0.10 1.07 0.014 0.08 ± 0.07
0.20 1.10 0.014 0.24 ± 0.08
3.85 1.51 0.021 3.38 ± 0.21
5.00 1.70 0.021 5.58 ± 0.28
10.0 1.97 0.021 9.99 ± 0.43
50.0 2.71 0.028 49.49 ± 3.83
100 2.93 0.035 101.7 ± 15.0
500 3.14 0.028 482.6 ± 184.7
1000 3.19 0.028 1269.6 ± 560
The mean values and the standard deviations of the detected IMR signals are
shown. Using the detected IMR signals, the CEA concentrations, ϕCEA-IMR,
derived using Eq. (1), are listed in the right-most column.
Table 3 Comparison of the low-detection limit and the
dynamic range of a CEA assay using commercially
available kits (e.g. Siemens, Abbott, and Roche) and






0.5 ng/ml 0.5 - 100 ng/ml USFDA
Abbott/AXSYM
system CEA assay
0.5 ng/ml 0.5 - 500 ng/ml USFDA
Roche/Elecsys CEA
assay
0.2 ng/ml 0.2 - 1,000 ng/ml USFDA, CE
This work 0.21 ng/ml 0.21 - 500 ng/ml None
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in-vitro diagnosis of colorectal cancer.
Linearity of assaying serum CEA
A careful inspection for Figure 4(a) shows that not every
data point lies on the solid line. If the experimental IMR
signals are used to derive the CEA concentration, using
Eq. (1), the derived CEA concentrations, ϕCEA-IMR, are
not exactly the same as those ϕCEA values that are
shown in Table 2. It is noted that ϕCEA denotes the
spiked CEA concentration in serum, but ϕCEA-IMR de-
notes the CEA concentration in serum, detected using
the IMR method. The correlation between ϕCEA-IMR and
ϕCEA is shown in Figure 4(b). Since the low-detection
limit for the assay of CEA using IMR method is 0.21 ng/
ml, a ϕCEA-IMR of 0.1-ng/ml CEA solution is not used in
Figure 4(b). Figure 4(b) shows the linear relationship be-
tween ϕCEA-IMR and ϕCEA. If the ϕCEA-IMR values for
CEA concentration ϕCEA values from 0.2 ng/ml to
1000 ng/ml are used in Figure 4(b), the slope of the
ϕCEA-IMR-ϕCEA curve is 1.21 and the coefficient of deter-
mination, R2, is 0.989, as plotted with the dashed line in
Figure 4(b). The US Food and Drug Administration
(FDA) regulations state that the slope of the line in
Figure 4(b) must be between 0.90 and 1.10. The slope of
the dashed line in Figure 4(b) does not meet the require-
ment of the US FDA. However, if the ϕCEA-IMR for a
CEA concentration ϕCEA of 1000 ng/ml is ignored, the
curve for ϕCEA-IMR against ϕCEA is linear and is plotted
with a solid line in Figure 4(b). The slope of this solid
line is 0.97 and the coefficient of determination, R2, is
0.999. It is worthy of note that the slope of the solid line
meets the requirement of the US FDA. The range of
CEA concentrations used for the solid line in Figure 4(b)
is from 0.2 ng/ml to 500 ng/ml, so the dynamic range of
the CEA concentration for IMR assay is 500 ng/ml.A comparison of the low-detection limit and the dy-
namic range of a CEA assay for commercially available
kits (e.g. Siemens, Abbott, and Roche) used in the work
is listed in Table 3. It is clear that the IMR assay for
CEA is highly sensitive and has a broad dynamic range,
which renders it suitable for clinical use.
Clinical tests for assaying serum CEA
Using the relationship shown in Figure 4(a), the CEA con-
centrations in human serum samples can be determined
using the IMR signals. 24 serum samples from healthy
subjects (Normal control) and 30 serum samples from pa-
tients with colorectal cancer (CRC) were used for the CEA
assay, using the IMR method. CRC patients were identi-
fied using either pathological evidence or an immuno-
assay. The detected CEA concentrations ϕCEA-IMR of these
serum samples are plotted in Figure 5(a). The ϕCEA-IMR
values for the normal control group are distributed over a
relatively lower range than those for CRC patients. Most
of ϕCEA-IMR values for the normal control group are within
the range, 0.6 ng/ml to 1.5 ng/ml, but the ϕCEA-IMR values
for CRC patients range from 6.0 ng/ml to 20 ng/ml. An
analysis of the receiver operating characteristic (ROC)
curve shown in Figure 5(b) shows that the threshold for
the diagnosis of CRC by an assay of CEA in serum, using
the IMR method, is 4.05 ng/ml, which results in the clinic
sensitivity of 0.90 and a specificity of 0.87.
Conclusions
Antibodies against carcinoembryonic antigen (CEA) are
conjugated onto magnetic nanoparticles, to synthesize a
magnetic reagent for the assay of CEA in serum. The re-
agent gives a highly stable particle suspension in pH-7.4
phosphate buffered saline (PBS) solution and CEA mole-
cules with a highly stable bio-activity, when the reagent is
stored at 2–8°C. The immunomagnetic reduction method
gives a low-detection threshold for the assay of CEA is
0.21 ng/ml and the dynamic range is 500 ng/ml. There is
no significant interference with the assay of CEA in serum
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Figure 5 Comparison of serum CEA concentration for normal
controls and CRC. (a) CEA concentration, ϕCEA-IMR, for normal
subjects (normal control) and patients with colorectal cancer (CRC),
detected using the immunomagnetic reduction method, and (b)
the ROC curve for the analysis of the clinical sensitivity and the
specificity for the diagnosis of colorectal cancer, using the detected
CEA concentration ϕCEA-IMR in serum.
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concentration in 54 serum samples show that the clinical
sensitivity and the specificity for the diagnosis of colorectal
cancer are 0.90 and 0.87, respectively, with a threshold of
4.05 ng/ml.Methods
Synthesis of bio-magnetic nanoparticles
The protocol for the synthesis of magnetic Fe3O4 nanopar-
ticles is proposed by MagQu Co., Ltd [25]. A ferrite solution
containing ferrous sulphate hepta-hydrate (FeSO4⋅7H2O)
and ferric chloride hexa-hydrate (FeCl3⋅6H2O) in a stoichio-
metric ratio of 1:2 was mixed with an equal volume of
aqueous dextran, which acts as a surfactant for Fe3O4 par-
ticles dispersed in water. The mixture was heated to 70–
90°C and titrated with a strong base solution, to form
black Fe3O4 particles. Aggregates and excess unbound
dextran were removed by centrifugation and gel filtration
chromatography, to produce a highly concentrated ho-
mogeneous magnetic fluid. The reagent (MF-DEX-0060,
MagQu) with the desired magnetic concentration was ob-
tained by diluting the highly concentrated magnetic fluid
with pH-7.4 phosphate buffered saline (PBS) solution. To
ensure that the antibodies against carcinoembryonic anti-
gen (CEA) for colorectal cancer, i.e. anti-CEA (AT-CEA,
MagQu), bound to the dextran on the outmost shell of
magnetic nanoparticles, NaIO4 solution was added into
the magnetic solution to oxidize the dextran, which then
creates aldehyde groups (−CHO). The dextran then reacts
with anti-CEA via the linking of –CH=N-, so anti-CEA is
bound covalently to dextran, as schematically shown in
Figure 1(a). Unbound anti-CEA was separated from the
solution by magnetic separation.
Characterizations of bio-magnetic nanoparticles
The distribution of the size of Fe3O4 magnetic nanoparti-
cles bio-functionalized with anti-CEA was determined by
dynamic laser scattering (Nanotrac 150, Microtrac). To de-
termine the immuno reactivity of anti-CEA functionalized
Fe3O4 magnetic nanoparticles, so-called immunomagnetic
reduction was used [13,26,27]. In immunomagnetic reduc-
tion, antibody functionalized magnetic nanoparticles were
mixed with a solution of target bio-molecules. Before the
nanoparticles and CEA molecules associated, the ac mag-
netic susceptibility χac,o of the mixture was detected, using
an ac magnetosusceptometer (XacPro-E, MagQu). Nano-
particles associate with target bio-molecules, via the anti-
bodies on the magnetic nanoparticles. This association
results in a reduction in the ac magnetic susceptibility of
the mixture. The ac susceptibility of the mixture after as-
sociation is denoted by χac,ϕ. The reduction in ac suscepti-
bility is referred to as the IMR signal and is expressed as:





For each IMR signal measurement, 40-μl reagent and
60-μl CEA solution or sample were used.
According to Ref. [28], the total number of antibody
functionalized magnetic nanoparticles in 1-ml, 8-mg-Fe/
ml magnetic bio-reagent is roughly 1013 particles. There
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nanoparticle. For IMR measurement, the used volume of
reagent is 40 μl. Hence, 2.4 × 1012 anti-CEA molecules
are used for each IMR test.
Preparation of standard CEA solutions
Standard CEA (Human CD66e) protein was obtained
from AdD Serotec (Cat. No. PHP282). Various concentra-
tions of CEA protein were prepared by serially diluting
standard CEA protein with PBS buffer or normal free
serum and the resulting solution was stored at −80°C. The
concentration of CEA protein was then quantified using a
spectrophotometer (NanoDrop2000; Thermo Scientific.).
Assessment of human serum CEA
24 serum samples from healthy subjects (Normal control)
and 30 serum samples from patients with colorectal cancer
(CRC) were used for the CEA assay. The CEA concentra-
tions in human serum samples will be determined using
the IMR signals. CRC patients were identified using either
pathological evidence or an immunoassay. All of the en-
rolled patients provided informed consent before undergo-
ing the procedure and this study was approved by National
Taiwan University Hospital Research Ethics Committee
(No.201105996RC).
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